Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2013

Peeters Marc, Oliner Kelly S, Parker Alex, Siena Salvatore, Van Cutsem Eric, Huang Jing, Humblet Yves, Van Laethem Jean-Luc, André Thierry, Wiezorek Jeffrey, Reese David, Patterson Scott D

Abstract excerpt

PURPOSE: To investigate whether EGF receptor (EGFR) pathway mutations predicted response to monotherapy with panitumumab, an anti-EGFR monoclonal antibody, in a randomized phase III study of metastatic colorectal cancer. EXPERIMENTAL DESIGN: Using massively parallel multigene sequencing, we analyzed 320 samples for 9 genes, with multigene sequence data from 288 (90%) samples. RESULTS: Mutation rates were: KRAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Genes, ras

Share to Multilocus Sequence Typing

Share to Mutation Rate

Share to Neoplasm Metastasis

Share to Panitumumab

Source

Identifiers

PMID: 23325582
DOI: 10.1158/1078-0432.CCR-12-1913

Genes

KRAS
NRAS
BRAF
EGFR
CTNNB1
PTEN
AKT1
EGF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.PMID 23325582Read ↗

Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.Semantic proximity Read ↗

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patientsSemantic proximity Read ↗

The Role of Multigene Panel Next-Generation Sequencing Techniques in Managing Patients with Metastatic Colorectal CarcinomaSemantic proximity Read ↗

Multigene Panel Next-Generation Sequencing Techniques in the Management of Patients with Metastatic Colorectal Carcinoma: The Way Forward for Personalized Treatment? A Single-Center Experience.Semantic proximity Read ↗

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.Semantic proximity Read ↗

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.Semantic proximity Read ↗

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.Semantic proximity Read ↗

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read ↗

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.